Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone857-242-0170
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees59
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions
What is Magenta Therapeutics' stock symbol?
Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."
How were Magenta Therapeutics' earnings last quarter?
Magenta Therapeutics Inc (NASDAQ:MGTA) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.01. View Magenta Therapeutics' Earnings History.
When is Magenta Therapeutics' next earnings date?
What price target have analysts set for MGTA?
4 brokers have issued 1 year price targets for Magenta Therapeutics' shares. Their forecasts range from $16.00 to $22.00. On average, they anticipate Magenta Therapeutics' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 90.0% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics.
What is the consensus analysts' recommendation for Magenta Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics.
Has Magenta Therapeutics been receiving favorable news coverage?
News stories about MGTA stock have trended negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Magenta Therapeutics earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Magenta Therapeutics.
Who are some of Magenta Therapeutics' key competitors?
Some companies that are related to Magenta Therapeutics include Tricida (TCDA), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Radius Health (RDUS), Turning Point Therapeutics (TPTX), Zymeworks (ZYME) and Innoviva (INVA).
What other stocks do shareholders of Magenta Therapeutics own?
Who are Magenta Therapeutics' key executives?
Magenta Therapeutics' management team includes the folowing people:
- Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)
- Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)
- Ms. Alison Lawton, Board Advisor (Age 58)
- Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)
- Ms. Manisha Pai, VP of Investor Relations & Communications
When did Magenta Therapeutics IPO?
(MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Magenta Therapeutics?
Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Magenta Therapeutics' stock price today?
One share of MGTA stock can currently be purchased for approximately $10.00.
How big of a company is Magenta Therapeutics?
Magenta Therapeutics has a market capitalization of $393.38 million. The company earns $-57,510,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.View Additional Information About Magenta Therapeutics.
What is Magenta Therapeutics' official website?
How can I contact Magenta Therapeutics?
Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]
MarketBeat Community Rating for Magenta Therapeutics (NASDAQ MGTA)
MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote "Outperform" if you believe MGTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
